Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395017 · ClinicalTrials.gov registry record · Phase 2
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
NCT01395017: Completed Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT01395017 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 202 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01395017, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
Primary Outcome
Overall survival (OS) is the time from randomization until time of death from any cause by 02 December 2013.
Interventions
- DRUG Placebo
- DRUG dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT01395017 record still lists
NCT01395017 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01395017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01395017 about?
NCT01395017 is a clinical study titled "Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer". The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
What is the current status of trial NCT01395017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2011-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01395017?
The interventions under investigation include: Placebo (DRUG), dasatinib (DRUG).
Who is sponsoring clinical trial NCT01395017?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01395017's enrollment target sits among peer trials
202 301st of 2000 higher than 1,699 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia